Benefit from b-lymphocyte depletion using the anti-cd20 antibody rituximab in chronic fatigue syndrome. a double-blind and placebo-controlled study

HIGHLIGHTS

• who: Øystein Fluge and collaborators from the Department of Oncology and Medical Physics, Haukeland University Hospital, Department of Medical Genetics and Molecular Medicine, HaukelandEditor: Markus Reindl, Innsbruck Medical University, Austria have published the paper: Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study, in the Journal: (JOURNAL) of October/19,/2011
• what: The aim was to evaluate the use of B-cell depletion with the anti-CD20 monoclonal antibody Rituximab for CFS symptom relief, during 12 months follow-up. This study with . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.